Skip to main content

Table 2 Comparisons of the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity of autoantibody isotypes against unmodified and 4-hydroxy-2-nonenal (HNE)-modified peptides in rheumatoid arthritis (RA) patients and osteoarthritis (OA) patients compared to healthy controls (HCs)

From: Isotypes of autoantibodies against novel differential 4-hydroxy-2-nonenal-modified peptide adducts in serum is associated with rheumatoid arthritis in Taiwanese women

Peptides RA vs. HC OA versus HC p value a
AUC (95%CI) Sensitivity (95%CI) Specificity (95%CI) AUC (95%CI) Sensitivity (95%CI) Specificity (95%CI)
IgG anti-CFAH1121−1230 0.66 (0.57–0.76) 63.3% (49.9–75.4) 51.7% (38.4–64.8) 0.58 (0.46–0.70) 60.0% (42.1–76.1) 60.0% (46.5–72.4) 0.6844
Cutoff (OD450)   > 0.24    < 0.21   
IgG anti-CFAH1121−1230 HNE 0.71 (0.62–0.80) 76.7% (64.0–86.6) 55.0% (41.6–67.9) 0.52 (0.40–0.64) 51.4% (34.0–68.6) 50.0% (36.8–63.2) 0.0135
Cutoff (OD450)   > 0.21    < 0.20   
IgM anti-CFAH1121−1230 0.68 (0.59–0.78) 81.7% (69.6–90.5) 53.3% (40.0–66.3) 0.68 (0.58–0.79) 77.1% (59.9–89.6) 60.0% (46.5–72.4) 0.4816
Cutoff (OD450)   > 0.58    > 0.63   
IgM anti-CFAH1121−1230 HNE 0.70 (0.61–0.79) 85.0% (73.4–92.9) 41.7% (29.1–55.1) 0.59 (0.47–0.71) 80.0% (63.1–91.6) 36.7% (24.6–50.1) 0.0421
Cutoff (OD450)   > 0.24    > 0.23   
IgG anti-HPT78−108 0.67 (0.58–0.77) 71.7% (58.6–82.6) 55.0% (41.6–67.9) 0.53 (0.41–0.65) 51.4% (34.0–68.6) 46.7% (33.7–60.0) 0.3711
Cutoff (OD450)   > 0.64    < 0.64   
IgG anti-HPT78−108 HNE 0.66 (0.57–0.76) 71.7% (58.6–82.6) 48.3% (35.2–61.6) 0.58 (0.46–0.70) 62.9% (44.9–78.5) 55.0% (41.6–67.9) 0.8974
Cutoff (OD450)   > 0.25    < 0.25   
IgM anti-HPT78−108 0.67 (0.57–0.77) 71.7% (58.6–82.6) 56.7% (43.2–69.4) 0.53(0.40–0.66) 51.4%(33.9–68.6) 50.0%(36.8– 63.2) 0.2823
Cutoff (OD450)   > 0.30    < 0.29   
IgM anti-HPT78−108 HNE 0.89 (0.80–0.93) 86.7% (75.4–94.1) 66.7% (53.3–78.3) 0.58 (0.46–0.69) 65.7% (47.8–80.9) 55.0% (41.6–67.9) < 0.0001
Cutoff (OD450)   > 0.20    > 0.16   
IgG anti-IGKC2−19 0.72 (0.62–0.81) 80.0% (67.7–89.2) 60.0% (46.5–72.4) 0.59 (0.47–0.70) 65.7% (47.8–80.9) 53.3% (40.0–66.3) 0.1471
Cutoff (OD450)   > 0.41    > 0.37   
IgG anti-IGKC2−19 HNE 0.70 (0.61–0.79) 78.3% (65.8–87.9) 56.7% (43.2–69.4) 0.55 (0.43–0.67) 65.7% (47.9–80.9) 50.0% (36.8–63.2) 0.0917
Cutoff (OD450)   > 0.45    > 0.39   
IgM anti-IGKC2−19 0.83 (0.75–0.90) 81.7% (69.6–90.5) 60.0% (46.5–72.4) 0.56 (0.44–0.68) 57.1% (39.4–73.7) 50.0% (36.8–63.2) < 0.0001
Cutoff (OD450)   > 0.61    > 0.53   
IgM anti-IGKC2−19 HNE 0.86 (0.79–0.93) 83.3% (71.5–91.7) 66.7% (53.3–78.3) 0.58 (0.46–0.70) 68.6% (50.7–83.2) 51.7% (38.4–64.8) < 0.0001
Cutoff (OD450)   > 0.37    > 0.32   
IgG anti-THRB328−345 0.70 (0.61–0.79) 66.7% (53.3–78.3) 53.3% (40.0–66.3) 0.53 (0.42–0.65) 62.9% (44.9–78.5) 48.3% (35.2–61.6) 0.0086
Cutoff (OD450)   > 0.20    > 0.19   
IgG anti-THRB328−345 HNE 0.75 (0.67–0.84) 80.0% (67.7–89.2) 53.3% (40.0–66.3) 0.60 (0.48–0.71) 68.6% (50.7–83.2) 50.0% (36.8–63.2) 0.0087
Cutoff (OD450)   > 0.32    > 0.31   
IgM anti-THRB328−345 0.63 (0.53–0.73) 63.3% (50.0–75.4) 53.3% (40.0–66.3) 0.56 (0.44–0.68) 60.0% (42.1–76.1) 53.3% (40.0–66.3) 0.5845
Cutoff (OD450)   > 0.61    > 0.60   
IgM anti-THRB328−345 HNE 0.78 (0.69–0.86) 76.7% (64.0–86.6) 71.7% (58.6–82.6) 0.56 (0.44–0.68) 65.7% (47.8–80.9) 46.7% (33.7–60.0) 0.0001
Cutoff (OD450)   > 0.64    > 0.52   
  1. aPairwise comparison of predictive performance, HC-RA versus HC-OA, was performed by Student’s t-test
\